 NEW YORK, April 09, 2021 GLOBE NEWSWIRE -- Cellectis S.A. NASDAQ: CLLS EURONEXT GROWTH: ALCLS the Company, a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, today announced that it has completed sales of approximately 47 million of American Depositary Shares ADS pursuant to the Companys ATM program established on March 29, 2021 the ATM Sales, through Jefferies LLC Jefferies, acting as sales agent. Each ADS represents one ordinary share of the Company. 